Fenofibrate Is Effective in Treating Hypertriglyceridemia Associated with HIV-related Lipodystrophy 

The aim of the current study was to determine the effectiveness of fenofibrate in treating hypertriglyceridemia associated with highly active antiretroviral therapy-associated HIV lipodystrophy syndrome (HLS).

The authors recruited from their HIV metabolic clinic 55 adult patients with anthropomorphic changes consistent with HLS together with hypertriglyceridemia. The patients had no prior history of taking lipid-lowering medications and were free of liver and renal disease. They were on various HAART regimens, and these regimens were not altered during the course of the study.

Fenofibrate was started at 54 mg a day and the dose increased every 2 weeks to a maximum of 162 mg/day. Fasting lipid concentrations were measured at baseline and 6 months after the intervention.

Results

At baseline, the fasting plasma concentrations of total cholesterol, triglyceride, and high-density lipoprotein (HDL) cholesterol were 259 +/- 11, 886 +/- 172, and 35.7 +/- 2.3 (mean +/- SEM) mg/dL, respectively.

After 6 months of fenofibrate treatment, the fasting plasma concentrations were as follows: total cholesterol, 243 +/- 13; triglycerides, 552 +/- 104, and HDL cholesterol, 35.7 +/- 1.8 mg/dL.

The decrease in fasting plasma triglyceride concentration was statistically significant (P < 0.05).

Fenofibrate was well tolerated, and no subjects dropped out of the study.

Conclusion

Fenofibrate is an effective, well-tolerated treatment for hypertriglyceridemia associated with HLS.

Division of Endocrinology, Baylor College of Medicine, and Endocrine Service, Ben Taub General Hospital, Houston, Texas, USA.

08/02/04